WHAT IS CLAIMED IS:

1. Use of an IL-17A and/or IL-17F antagonist in the manufacture of a medicament for the treatment of an insulin-resistant disorder.
2. The use of claim 1, comprising administering to a mammal in need thereof an effective amount of an IL-17A and/or IL-17F antagonist.
3. The use of claim 2, wherein the mammal is human and the administration is systemic.
4. The use of claim 1, wherein the disorder is selected from the group consisting of non-insulin dependent diabetes mellitus (NIDDM), obesity, ovarian hyperandrogenism, and hypertension.
5. The use of claim 4, wherein the disorder is NIDDM or obesity.
6. The use of any of claims 1 to 5, wherein the IL-17A and/or IL-17F antagonist is an antibody or a fragment thereof.
7. The use of claim 6, wherein the antibody is an antibody selected from the group consisting of anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-17Rc and anti-IL-17RA antibodies.
8. The use of claim 7, wherein the antibody is a monoclonal antibody.
9. The use of claim 8, wherein the antibody is a chimeric, humanized or human antibody.
10. The use of claim 9, wherein the antibody is a bispecific, multispecific or cross-reactive antibody.
11. The use of claim 7, wherein the medicament further comprises an effective amount of an insulin-resistance-treating agent.
12. The use of claim 11, wherein the insulin-resistance-treating agent is insulin, IGF-1, or a sulfonylurea.
13. The use of claim 12, wherein the medicament further comprises an effective amount of a further agent capable of treating said insulin-resistance disorder.
14. The use of claim 13, wherein the further agent is Dickkopf-5 (Dkk-5).
15. A pharmaceutical composition comprising an IL-17A and/or IL-17F antagonist in admixture with a pharmaceutically acceptable excipient, for use in treatment of an insulin-resistant disorder.
16. The pharmaceutical composition of claim 15, comprising an IL-17A and/or IL-17F antagonist according to any one of claims 6 to 10.

17. A kit for treating an insulin-resistant disorder, said kit comprising: (a) a container comprising an IL-17A and/or IL-17F antagonist; and (b) a label or instructions for administering said antibody to treat said disorder.

CLAIMS

1. Use of an IL-17A and/or IL-17F antibody, or an antigen-binding fragment thereof, in the manufacture of a medicament for the treatment of an insulin-resistant disorder, wherein the disorder is selected from the group consisting of non-insulin dependent diabetes mellitus (NIDDM), obesity, ovarian hyperandrogenism, and hypertension.
2. The use of claim 1, comprising administering to a mammal in need thereof an effective amount of an IL-17A and/or IL-17F antibody.
3. The use of claim 2, wherein the mammal is human and the administration is systemic.
4. The use of claim 1, wherein the disorder is NIDDM or obesity.
5. The use of claim 4, wherein the antibody is an antibody selected from the group consisting of anti-IL-17A, anti-IL-17F, and anti-IL-17A/F antibodies.
6. The use of claim 5, wherein the antibody is a monoclonal antibody.
7. The use of claim 6, wherein the antibody is a chimeric, humanized or human antibody.
8. The use of claim 7, wherein the antibody is a bispecific, multispecific or cross-reactive antibody.
9. The use of claim 5, wherein the medicament further comprises an effective amount of an insulin-resistance-treating agent.
10. The use of claim 9, wherein the insulin-resistance-treating agent is insulin, IGF-1, or a sulfonylurea.
11. The use of claim 10, wherein the medicament further comprises an effective amount of a further agent capable of treating said insulin-resistance disorder.
12. The use of claim 11, wherein the further agent is Dickkopf-5 (Dkk-5).
13. A kit for treating an insulin-resistant disorder, said kit comprising: (a) a container comprising an IL-17A and/or IL-17F antibody; and (b) a label or instructions for administering said antibody to treat said disorder, wherein the disorder is selected from the group consisting of non-insulin dependent diabetes mellitus (NIDDM), obesity, ovarian hyperandrogenism, and hypertension.